Skip to main content
Top
Published in: Calcified Tissue International 6/2003

01-12-2003 | Laboratory Investigations

A Rapid Multiparameter Approach to Study Factors that Regulate Osteoclastogenesis: Demonstration of the Combinatorial Dominant Effects of TNF-α and TGF-ß in RANKL-Mediated Osteoclastogenesis

Authors: W. Huang, M.H. Drissi, R. J. O’Keefe, E.M. Schwarz

Published in: Calcified Tissue International | Issue 6/2003

Login to get access

Abstract

Macrophages differentiate into osteoclasts in response to the critical cytokine RANKL. However, the efficiency of RANKL-mediated osteoclastogenesis can be profoundly influenced by various cytokines. While studies describing the isolated effects of particular cytokines on osteoclastogenesis have been performed, combinatorial effects of cytokines have not been addressed routinely due to the absence of an efficient assay system. To study the effects of cytokine combinations on osteoclast formation, we performed in vitro assays using either the RAW293 cell line or primary murine splenic macrophages as osteoclast precursors. Using a multiparameter cytokine plating method, we analyzed osteoclastogenesis in response to multiple combinations of the following inflammation-related cytokines: RANKL, IFN-γ, TNF-α, IL-1β, IL-6, IL-10. We further investigated the role of T-cell-related cytokine combinations on osteoclastogenesis by measuring osteoclast area in response to RANKL with IFN-γ, IL-2, IL-4, IL-6, TGF-ß, and TNF-α. Treatments with RANKL, TNF-α, and TGF-ß induced maximal osteoclast formation, suggesting a role for these cytokines in the most aggressive forms of inflammatory bone loss. TNF-α alone, however, was unable to induce osteoclast formation in the absence of RANKL despite co-administration of other proinflammatory cytokines. IFN-γ was a potent inhibitor under all conditions, implicating T cells and NK cells in osteoclast inhibition. These studies demonstrate a rapid screening approach for identifying the potential collective effects of multiple factors on osteoclastic bone resorption.
Literature
1.
go back to reference Huang, W, Schwarz, EM 2002Mechanisms of bone resorption and new bone formation in spondyloarthropathies.Curr Rheumatol Rep4513517CrossRefPubMed Huang, W, Schwarz, EM 2002Mechanisms of bone resorption and new bone formation in spondyloarthropathies.Curr Rheumatol Rep4513517CrossRefPubMed
2.
go back to reference Greenfield, EM, Bi, Y, Miyauchi, A 1999Regulation of osteoclast activity.Life Sci6510871102CrossRefPubMed Greenfield, EM, Bi, Y, Miyauchi, A 1999Regulation of osteoclast activity.Life Sci6510871102CrossRefPubMed
3.
go back to reference Hofbauer, LC, Khosla, S, Dunstan, CR, Lacey, DL, Boyle, WJ, Riggs, BL 2000The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res15212CrossRefPubMed Hofbauer, LC, Khosla, S, Dunstan, CR, Lacey, DL, Boyle, WJ, Riggs, BL 2000The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res15212CrossRefPubMed
5.
go back to reference Xing, L, Carlson, L, Story, B, Tai, Z, Keng, P, Siebenlist, U, Boyce, BF 2003Expression of either NF-kappa B p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption.J Bone Miner Res18260269CrossRefPubMed Xing, L, Carlson, L, Story, B, Tai, Z, Keng, P, Siebenlist, U, Boyce, BF 2003Expression of either NF-kappa B p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption.J Bone Miner Res18260269CrossRefPubMed
6.
go back to reference Udagawa, N, Takahashi, N, Katagiri, T, Tamura, T, Wada, S, Findlay, DM, Martin, TJ, Hirota, H, Taga, T, Kishimoto, T 1995Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors.J Exp Med18214611468CrossRefPubMed Udagawa, N, Takahashi, N, Katagiri, T, Tamura, T, Wada, S, Findlay, DM, Martin, TJ, Hirota, H, Taga, T, Kishimoto, T 1995Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors.J Exp Med18214611468CrossRefPubMed
7.
go back to reference Lam, J, Takeshita, S, Barker, JE, Kanagawa, O, Ross, FP, Teitelbaum, SL 2000TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.J Clin Invest10614811488CrossRefPubMedPubMedCentral Lam, J, Takeshita, S, Barker, JE, Kanagawa, O, Ross, FP, Teitelbaum, SL 2000TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.J Clin Invest10614811488CrossRefPubMedPubMedCentral
8.
go back to reference Kobayashi, K, Takahashi, N, Jimi, E, et al. 2000Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.J Exp Med191275286CrossRefPubMedPubMedCentral Kobayashi, K, Takahashi, N, Jimi, E,  et al. 2000Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.J Exp Med191275286CrossRefPubMedPubMedCentral
9.
go back to reference Wei, S, Wang, MW, Teitelbaum, SL, Ross, FP 2002Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling.J Biol Chem27766226630CrossRefPubMed Wei, S, Wang, MW, Teitelbaum, SL, Ross, FP 2002Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling.J Biol Chem27766226630CrossRefPubMed
10.
go back to reference Takayanagi, H, Ogasawara, K, Hida, S, et al. 2000T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.Nature408600605CrossRefPubMed Takayanagi, H, Ogasawara, K, Hida, S,  et al. 2000T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.Nature408600605CrossRefPubMed
11.
go back to reference Hong, MH, Williams, H, Jin, CH, Pike, JW 2000The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins.J Bone Miner Res15911918CrossRefPubMed Hong, MH, Williams, H, Jin, CH, Pike, JW 2000The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins.J Bone Miner Res15911918CrossRefPubMed
12.
go back to reference Yamada, N, Niwa, S, Tsujimura, T, Iwasaki, T, Sugihara, A, Futani, H, Hayashi, S, Okamura, H, Akedo, H, Terada, N 2002Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity.Bone30901908CrossRefPubMed Yamada, N, Niwa, S, Tsujimura, T, Iwasaki, T, Sugihara, A, Futani, H, Hayashi, S, Okamura, H, Akedo, H, Terada, N 2002Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity.Bone30901908CrossRefPubMed
13.
go back to reference Kotake, S, Udagawa, N, Takahashi, N, et al. 1999IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.J Clin Invest10313451352CrossRefPubMedPubMedCentral Kotake, S, Udagawa, N, Takahashi, N,  et al. 1999IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.J Clin Invest10313451352CrossRefPubMedPubMedCentral
14.
go back to reference Horwood, NJ, Udagawa, N, Elliott, J, Grail, D, Okamura, H, Kurimoto, M, Dunn, AR, Martin, T, Gillespie, MT 1998Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor.J Clin Invest101595603CrossRefPubMedPubMedCentral Horwood, NJ, Udagawa, N, Elliott, J, Grail, D, Okamura, H, Kurimoto, M, Dunn, AR, Martin, T, Gillespie, MT 1998Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor.J Clin Invest101595603CrossRefPubMedPubMedCentral
15.
go back to reference Rook, G 2001Th1- or Th2-cell commitment during infectious disease: an oversimplification?Trends Immunol22481482CrossRefPubMed Rook, G 2001Th1- or Th2-cell commitment during infectious disease: an oversimplification?Trends Immunol22481482CrossRefPubMed
16.
go back to reference Hanada, T, Yoshimura, A 2002Regulation of cytokine signaling and inflammation.Cytokine Growth Factor Rev13413421CrossRefPubMed Hanada, T, Yoshimura, A 2002Regulation of cytokine signaling and inflammation.Cytokine Growth Factor Rev13413421CrossRefPubMed
17.
go back to reference Amizuka, N, Henderson, JE, White, JH, Karaplis, AC, Goltzman, D, Sasaki, T, Ozawa, H 2000Recent studies on the biological action of parathyroid hormone (PTH)-related peptide (PTHrP) and PTH/PTHrP receptor in cartilage and bone.Histol Histopathol15957970PubMed Amizuka, N, Henderson, JE, White, JH, Karaplis, AC, Goltzman, D, Sasaki, T, Ozawa, H 2000Recent studies on the biological action of parathyroid hormone (PTH)-related peptide (PTHrP) and PTH/PTHrP receptor in cartilage and bone.Histol Histopathol15957970PubMed
18.
go back to reference Sells Galvin, RJ, Gatlin, CL, Horn, JW, Fuson, TR 1999TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF.Biochem Biophys Res Commun265233239CrossRefPubMed Sells Galvin, RJ, Gatlin, CL, Horn, JW, Fuson, TR 1999TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF.Biochem Biophys Res Commun265233239CrossRefPubMed
19.
go back to reference Lacey, DL, Timms, E, Tan, HL, et al. 1998Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.Cell93165176CrossRefPubMed Lacey, DL, Timms, E, Tan, HL,  et al. 1998Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.Cell93165176CrossRefPubMed
20.
go back to reference Abu-Amer, Y, Ross, FP, Edwards, J, Teitelbaum, SL 1997Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor.J Clin Invest10015571565CrossRefPubMedPubMedCentral Abu-Amer, Y, Ross, FP, Edwards, J, Teitelbaum, SL 1997Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor.J Clin Invest10015571565CrossRefPubMedPubMedCentral
21.
go back to reference Wei, S, Wang, MW, Teitelbaum, SL, Ross, FP 2001Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-{kappa}B and MAP kinase signaling.J Biol Chem2121 Wei, S, Wang, MW, Teitelbaum, SL, Ross, FP 2001Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-{kappa}B and MAP kinase signaling.J Biol Chem2121
22.
23.
go back to reference Dalton, DK, Pitts-Meek, S, Keshav, S, Figari, IS, Bradley, A, Stewart, TA 1993Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.Science25917391742CrossRefPubMed Dalton, DK, Pitts-Meek, S, Keshav, S, Figari, IS, Bradley, A, Stewart, TA 1993Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.Science25917391742CrossRefPubMed
24.
go back to reference Abramson, SB, Amin, A 2002Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.Rheumatology (Oxford)41972980CrossRef Abramson, SB, Amin, A 2002Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.Rheumatology (Oxford)41972980CrossRef
Metadata
Title
A Rapid Multiparameter Approach to Study Factors that Regulate Osteoclastogenesis: Demonstration of the Combinatorial Dominant Effects of TNF-α and TGF-ß in RANKL-Mediated Osteoclastogenesis
Authors
W. Huang
M.H. Drissi
R. J. O’Keefe
E.M. Schwarz
Publication date
01-12-2003
Publisher
Springer New York
Published in
Calcified Tissue International / Issue 6/2003
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-003-0059-8

Other articles of this Issue 6/2003

Calcified Tissue International 6/2003 Go to the issue

Announcements

Announcements

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.